Morgan Stanley
INMB icon

Morgan Stanley’s INmune Bio INMB Stock Holding History

Morgan Stanley’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.4K Sell
44,611
-77,901
-64% -$111K ﹤0.01% 6418
2025
Q4 		$191K Buy
122,512
+46,802
+62% +$83.5K ﹤0.01% 5951
2025
Q3 		$157K Sell
75,710
-27,028
-26% -$61.9K ﹤0.01% 5980
2025
Q2 		$237K Buy
102,738
+18,274
+22% +$134K ﹤0.01% 5788
2025
Q1 		$660K Sell
84,464
-70,662
-46% -$561K ﹤0.01% 5205
2024
Q4 		$724K Buy
155,126
+62,982
+68% +$328K ﹤0.01% 5251
2024
Q3 		$497K Buy
92,144
+63,769
+225% +$453K ﹤0.01% 5411
2024
Q2 		$250K Buy
28,375
+896
+3% +$8.83K ﹤0.01% 5582
2024
Q1 		$323K Buy
27,479
+1,873
+7% +$22.6K ﹤0.01% 5522
2023
Q4 		$288K Buy
25,606
+21,525
+527% +$180K ﹤0.01% 5811
2023
Q3 		$27.6K Sell
4,081
-913
-18% -$7.57K ﹤0.01% 6386
2023
Q2 		$45.3K Buy
4,994
+177
+4% +$1.42K ﹤0.01% 6245
2023
Q1 		$31.1K Buy
4,817
+1,829
+61% +$14.7K ﹤0.01% 6458
2022
Q4 		$18.9K Sell
2,988
-126,012
-98% -$894K ﹤0.01% 6712
2022
Q3 		$800K Sell
129,000
-79,282
-38% -$696K ﹤0.01% 5011
2022
Q2 		$1.84M Sell
208,282
-92,199
-31% -$686K ﹤0.01% 4601
2022
Q1 		$2.53M Sell
300,481
-78,006
-21% -$701K ﹤0.01% 4342
2021
Q4 		$3.86M Buy
378,487
+353,856
+1,437% +$5.24M ﹤0.01% 3986
2021
Q3 		$478K Buy
24,631
+13,088
+113% +$253K ﹤0.01% 5524
2021
Q2 		$203K Buy
11,543
+8,450
+273% +$114K ﹤0.01% 6010
2021
Q1 		$37K Buy
3,093
+1,526
+97% +$27.5K ﹤0.01% 6491
2020
Q4 		$27K Buy
1,567
+567
+57% +$5.34K ﹤0.01% 6352
2020
Q3 		$10K Buy
+1,000
New +$10.2K ﹤0.01% 6276

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley's INMB Position: Q1 2026 in Review

Morgan Stanley reduced its INmune Bio (INMB) stake by 64% in Q1 2026, selling an estimated $111K and leaving 44,611 shares worth $50.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6418.

Morgan Stanley first reported a position in INMB in Q3 2020 and has held it in 23 quarters since. The position peaked at $3.86M in Q4 2021. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Morgan Stanley held 44,611 shares of INmune Bio worth $50.4K as of Q1 2026.
  • Morgan Stanley sold 77,901 INmune Bio shares in Q1 2026, an estimated $111K.
  • INmune Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6418 holding.
  • Morgan Stanley first reported a position in INmune Bio in Q3 2020 and has held it in 23 quarters since.
  • Morgan Stanley's INmune Bio position peaked at $3.86M in Q4 2021.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.